Latest Tetrabenazine Stories

(Ivanhoe Newswire) -- No drug has been shown to improve the loss of the ability to move muscles voluntarily, until now. A new drug called pridopidine stabilizes dopamine signaling in areas of the brain that control movement and coordination. The findings were published online in the November 7 issue of The Lancet Neurology. "Pridopidine has the potential to complement available treatments by improving a different range of motor deficits," study authors were quoted as saying....

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal studyLundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea...

NEW YORK, Oct. 6 /PRNewswire/ -- The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday. All proceeds from the event go to the Woody and Marjorie Guthrie Research Fund, which has raised over $1,500,000 through this event. These funds help support the innovative HDSA Coalition...

DURHAM, N.C., Jan. 13 /PRNewswire/ -- S&R Communications Group has entered a strategic partnership with Ovation Pharmaceuticals, Inc., to launch Xenazine* (tetrabenazine), a treatment for chorea associated with Huntington's disease (HD). Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom. "In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine," said S&R President Paul Dreyer. "Having been...

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ -- - Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009 - Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship...

By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979. Over the years, he estimates, he has dispensed tetrabenazine -- or TBZ, as he calls it -- to 1,000 people with Huntington's disease, probably more than any doctor in the world. Tetrabenazine helps tame the uncontrollable movements, or "chorea," that characterize Huntington's, an inherited degenerative...

Ovation Pharmaceuticals has acquired from Prestwick Pharmaceuticals the exclusive license in the US to commercialize Xenazine, an orphan drug recently approved by the FDA for the treatment of chorea associated with Huntington's disease. Financial terms of the deal were not disclosed. Subsequently, Biovail, the Canadian pharmaceutical company, has acquired Prestwick. Under the terms of the agreement, Biovail and Ovation will jointly develop additional follow-on indications for Xenazine and...

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced it has acquired Prestwick Pharmaceuticals, Inc., a privately held, U.S.-based pharmaceutical company that holds the Canadian and U.S. licensing rights to Xenazine(R) (tetrabenazine tablets). Xenazine(R) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease. Xenazine(R) was granted Orphan Drug designation by the FDA, which provides the product with...

OVATION Pharmaceuticals, Inc. announced today that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine(R) (tetrabenazine), an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's Disease (HD). Financial terms of the deal were not disclosed. Subsequently, Biovail Corporation, Canada's largest publicly traded pharmaceutical company, acquired Prestwick....

Prestwick Pharmaceuticals has announced that the FDA has approved Xenazine for the treatment of chorea associated with Huntington's disease. Xenazine is said to be the first and only FDA-approved treatment for any symptom of Huntington's disease (HD) and is expected to be available later 2008. A double-blind, placebo-controlled, Phase III study found that Xenazine significantly reduced patients's chorea burden, improved global outcome scores, and was generally safe and well tolerated....